TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31157864

Group type: EXPERIMENTAL
Intervention: CEASE intervention with electronic tablet screener and motivational/educational videos; 2,764 smokers consented at visits.
Number of subjects: 6885

Group type: EXPERIMENTAL
Intervention: CEASE intervention with electronic tablet screener; 2,764 smokers consented at visits.
Number of subjects: 6885

Group type: EXPERIMENTAL
Intervention: Electronic screening for tobacco use; integrated into pediatric practice.
Number of subjects: 6885
Study: 31158075

Group type: EXPERIMENTAL
Intervention: Plasma glycosaminoglycan (GAG) score
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Total chondroitin sulfate concentration
Number of subjects: 175

Group type: COMPARATOR
Intervention: GAG scores
Number of subjects: 175
Study: 31158230

Group type: EXPERIMENTAL
Intervention: IMPROD biparametric MRI (bpMRI)
Number of subjects: 364
Study: 31158720

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 31159741

Group type: EXPERIMENTAL
Intervention: Digital multiplexed gene expression platform
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: RNA-Seq
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Individual PAM50 genes
Number of subjects: 96
Study: 31159801

Group type: EXPERIMENTAL
Intervention: Individualized structured dietary education for weight management (13 ± 5 sessions over 427 ± 223 days)
Number of subjects: 206
Study: 31159802

Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 38
Study: 31159810

Group type: EXPERIMENTAL
Intervention: Food Friends - Fun With New Foods® intervention delivered over 12 weeks by trained preschool teachers
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Food Friends - Fun With New Foods® intervention
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 250
Study: 31159817

Group type: EXPERIMENTAL
Intervention: Statin treatment (157 patients)
Number of subjects: 910

Group type: EXPERIMENTAL
Intervention: Statin treatment
Number of subjects: 910
Study: 31159873

Group type: EXPERIMENTAL
Intervention: SCD (n = 65)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: SCD APOE ε4 carriers
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: SCD APOE ε4 non-carriers
Number of subjects: 138

Group type: COMPARATOR
Intervention: Controls (n = 73)
Number of subjects: 138
Study: 31160198

Group type: EXPERIMENTAL
Intervention: Postinsertion computed tomography (CT)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Systematic literature review and meta-analysis
Number of subjects: 22
Study: 31160355

Group type: EXPERIMENTAL
Intervention: Genomic characterization of well-differentiated grade 3 pancreatic neuroendocrine tumor
Number of subjects: 0
Study: 31160383

Group type: EXPERIMENTAL
Intervention: TAK-228 (oral mTORC1/2 inhibitor) combined with TAK-117 (PI3Kα inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TAK-228 (oral mTORC1/2 inhibitor) combined with paclitaxel (chemotherapy)
Number of subjects: 0
Study: 31160680

Group type: EXPERIMENTAL
Intervention: Moving stimuli
Number of subjects: 22

Group type: COMPARATOR
Intervention: Static stimuli
Number of subjects: 22
Study: 31161046

Group type: EXPERIMENTAL
Intervention: Albumin (25%) boluses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal saline fluid boluses (placebo)
Number of subjects: 0
Study: 31161044

Group type: EXPERIMENTAL
Intervention: Sliding hip screw (SHS) and vitamin D supplementation (4000 IU daily for 6 months)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cancellous screws and vitamin D supplementation (4000 IU daily for 6 months)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sliding hip screw (SHS) and placebo
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cancellous screws and placebo
Number of subjects: 60
Study: 31161593

Group type: EXPERIMENTAL
Intervention: VFA-H group
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: BMI-H group
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: VFA
Number of subjects: 276
Study: 31161706

Group type: EXPERIMENTAL
Intervention: Benzodiazepines
Number of subjects: 0
Study: 31161734

Group type: EXPERIMENTAL
Intervention: Canakinumab 2 mg/kg subcutaneously every 8 weeks (4 mg/kg for NOMID patients)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Canakinumab
Number of subjects: 17
Study: 31161972

Group type: EXPERIMENTAL
Intervention: 3D ultrashort echo time (UTE) MRI
Number of subjects: 38

Group type: COMPARATOR
Intervention: CT (reference standard)
Number of subjects: 38
Study: 31163298

Group type: EXPERIMENTAL
Intervention: LO-V30M
Number of subjects: 96
Study: 31163440

Group type: EXPERIMENTAL
Intervention: Salivary pellicle from female subjects
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Salivary pellicle from male subjects
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no salivary pellicle)
Number of subjects: 50
Study: 31163675

Group type: EXPERIMENTAL
Intervention: Neuropsychological assessment using Bayley Scales of Infant Development (BSID) and Autism Diagnostic Observation Schedule (ADOS)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Total score of ADOS at 12 months
Number of subjects: 82
Study: 31164115

Group type: EXPERIMENTAL
Intervention: Predictive model based on initial weight loss, cancer type, appetite, and chronic obstructive pulmonary disease as predictors.
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: Risk-level 1 patients (WL < 3%, breast or hematologic cancer, no or little appetite loss)
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: Risk-level 5 patients (WL 3-5%)
Number of subjects: 628
Study: 31164172

Group type: EXPERIMENTAL
Intervention: Carbon Ion Radiotherapy (CIRT)
Number of subjects: 64
Study: 31164347

Group type: EXPERIMENTAL
Intervention: Baseline plasma samples analyzed by LC/MS from incident breast cancer cases.
Number of subjects: 422

Group type: COMPARATOR
Intervention: Matched controls from the SU.VI.MAX cohort.
Number of subjects: 422
Study: 31164394

Group type: EXPERIMENTAL
Intervention: 200 mg mifepristone followed by 400 μg sublingual misoprostol every 3 hours until expulsion
Number of subjects: 306
Study: 31164456

Group type: EXPERIMENTAL
Intervention: GC1118 (5.0 mg/kg)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: GC1118 (4.0 mg/kg)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: GC1118 in Cohort 1 (CRC without prior anti-EGFR treatment)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: GC1118 in Cohort 2 (CRC with tumors resistant to anti-EGFR therapy)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: GC1118 in Cohort 3 (EGFR-overexpressing gastric cancer)
Number of subjects: 63
Study: 31164926

Group type: EXPERIMENTAL
Intervention: Liraglutide (titrated from 0.6 mg q.d. to 1.8 mg q.d. over 4 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metformin (titrated from 500 mg b.i.d to 1000 mg b.i.d. over 4 weeks)
Number of subjects: 0
Study: 31164990

Group type: EXPERIMENTAL
Intervention: Fun For Wellness (FFW) online behavioral intervention
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 30
Study: 31165541

Group type: EXPERIMENTAL
Intervention: Whole breast once-weekly hypofractionated radiotherapy (wHF-RT) to a total dose of 30 Gy, in 5 fractions of 6 Gy
Number of subjects: 44
Study: 31165630

Group type: EXPERIMENTAL
Intervention: TECH-N participants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Notified partners
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participants overall
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 0
Study: 31165670

Group type: EXPERIMENTAL
Intervention: Age at menarche categorized (≤10, 11, 12, 13, 14, ≥15 years) with age 12 as reference
Number of subjects: 648
Study: 31165709

Group type: EXPERIMENTAL
Intervention: Power Up smartphone app
Number of subjects: 142

Group type: COMPARATOR
Intervention: Management as usual
Number of subjects: 142
Study: 31166442

Group type: EXPERIMENTAL
Intervention: Aerobic exercise for 1 month
Number of subjects: 9
Study: 31166554

Group type: EXPERIMENTAL
Intervention: Lipoabdominoplasty
Number of subjects: 20
Study: 31166567

Group type: EXPERIMENTAL
Intervention: Transient elastography for diagnosis of advanced liver fibrosis
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Clinical factors evaluated
Number of subjects: 400
Study: 31166701

Group type: EXPERIMENTAL
Intervention: Bridge-enhanced ACL repair (BEAR)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hamstring autograft
Number of subjects: 20

Group type: COMPARATOR
Intervention: Contralateral intact ACLs
Number of subjects: 20
Study: 31166857

Group type: EXPERIMENTAL
Intervention: Bacterial fluorescence imaging in combination with clinical evaluation of signs and symptoms (CSS)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Clinical evaluation of signs and symptoms (CSS) alone
Number of subjects: 19
Study: 31167051

Group type: EXPERIMENTAL
Intervention: Intensive glucose control (5.6 years of treatment)
Number of subjects: 1655

Group type: COMPARATOR
Intervention: Standard glucose control
Number of subjects: 1655
Study: 31167060

Group type: EXPERIMENTAL
Intervention: Macrolide treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no macrolide treatment)
Number of subjects: 0
Study: 31167654

Group type: EXPERIMENTAL
Intervention: Once-weekly semaglutide (0.5 and 1.0 mg)
Number of subjects: 3297

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3297

Group type: EXPERIMENTAL
Intervention: Once-weekly semaglutide
Number of subjects: 3297
Study: 31167802

Group type: EXPERIMENTAL
Intervention: Oral idasanutlin
Number of subjects: 0
Study: 31167890

Group type: EXPERIMENTAL
Intervention: Maternal pregestational type 1 diabetes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maternal prepregnancy BMI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Offspring metabolic risk factors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Offspring level of sCD163
Number of subjects: 0
Study: 31167965

Group type: EXPERIMENTAL
Intervention: COL7A1-modified autologous fibroblasts (3 intradermal injections of ~1 × 10^6 cells/cm2)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: COL7A1-modified autologous fibroblasts
Number of subjects: 4
Study: 31168327

Group type: EXPERIMENTAL
Intervention: Adiponectin concentration increase of 1 µg/mL
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Adiponectin concentration > median (2.8 ± 4.8 vs 4.2 ± 5.7)
Number of subjects: 197
Study: 31168381

Group type: EXPERIMENTAL
Intervention: Emergency percutaneous coronary intervention (PCI)
Number of subjects: 324
Study: 31168384

Group type: EXPERIMENTAL
Intervention: hs-cTn measurements at 0 hour/30 min algorithm
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: hs-cTn measurements at 0 hour/1 hour algorithm
Number of subjects: 1000

Group type: COMPARATOR
Intervention: hs-cTn measurements at 0 hour/3 hour algorithm
Number of subjects: 1000
Study: 31168392

Group type: EXPERIMENTAL
Intervention: B-type natriuretic peptide (BNP)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: N-terminus pro-brain natriuretic peptide (NT-proBNP)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: high-sensitivity troponin-T (hs-TnT)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: high-sensitivity troponin-I (hs-TnI)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: ST2
Number of subjects: 25
Study: 31168494

Group type: EXPERIMENTAL
Intervention: Rufinamide
Number of subjects: 37

Group type: COMPARATOR
Intervention: Any other approved antiseizure drug (ASD)
Number of subjects: 37
Study: 31168885

Group type: EXPERIMENTAL
Intervention: BMS-986231 (HNO donor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31169386

Group type: EXPERIMENTAL
Intervention: Self-reported cognitive difficulties
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Higher fatigue, pain, and depression levels
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Objective neuropsychological tests (Stroop I-IV, CVLT-II, WAIS-III, PASAT)
Number of subjects: 236
Study: 31169831

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 5072
Study: 31170515

Group type: EXPERIMENTAL
Intervention: Active monitoring for low-risk disease
Number of subjects: 2664

Group type: EXPERIMENTAL
Intervention: Radical treatment options for higher risk prostate cancer
Number of subjects: 2664

Group type: COMPARATOR
Intervention: Random allocation
Number of subjects: 2664

Group type: EXPERIMENTAL
Intervention: Patient preferences
Number of subjects: 2664
Study: 31170847

Group type: EXPERIMENTAL
Intervention: Bendamustine, carboplatin, and dexamethasone (BCD)
Number of subjects: 85
Study: 31170941

Group type: EXPERIMENTAL
Intervention: Healthy Primary School of the Future (HPSF) initiative including daily free healthy lunches and structured physical activity sessions
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Healthy Primary School of the Future (HPSF) initiative
Number of subjects: 4
Study: 31170954

Group type: EXPERIMENTAL
Intervention: Occlusal splint therapy
Number of subjects: 12
Study: 31171444

Group type: EXPERIMENTAL
Intervention: Neoadjuvant dabrafenib plus trametinib
Number of subjects: 35
Study: 31171638

Group type: EXPERIMENTAL
Intervention: Red blood cell transfusion dose density
Number of subjects: 1267

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 1267
Study: 31171735

Group type: EXPERIMENTAL
Intervention: Axitinib plus Crizotinib (starting doses: axitinib 3 mg plus crizotinib 200 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Axitinib plus Crizotinib
Number of subjects: 0
Study: 31171916

Group type: EXPERIMENTAL
Intervention: Teaching: Individual (nursing intervention)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 200
Study: 31171975

Group type: EXPERIMENTAL
Intervention: Parent-focused community health worker (CHW)-delivered lifestyle intervention
Number of subjects: 0
Study: 31172178

Group type: EXPERIMENTAL
Intervention: Low-protein (2%) overfeeding for 6 weeks
Number of subjects: 7

Group type: COMPARATOR
Intervention: 24-h fasting
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Low-protein overfeeding
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Increased 24EE above requirements for achieved body size post-overfeeding
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Baseline 24EE during 200% normal-protein overfeeding
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Serum FGF21 concentrations during overfeeding
Number of subjects: 7
Study: 31172977

Group type: EXPERIMENTAL
Intervention: Dolutegravir plus boosted-darunavir dual therapy
Number of subjects: 51
Study: 31173649

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-Piperaquine in young children
Number of subjects: 93
Study: 31174053

Group type: EXPERIMENTAL
Intervention: HeartMate II
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: ICD-related procedures post-LVAD
Number of subjects: 652

Group type: COMPARATOR
Intervention: LVAD infections
Number of subjects: 652
Study: 31174106

Group type: EXPERIMENTAL
Intervention: ICS/LABA/LAMA therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Liquid oxygen therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Three COPD exacerbations during follow-up
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ICS/LABA or ICS/LABA/LAMA associated therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CAT questionnaire score
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hospitals managed by local healthcare authorities
Number of subjects: 0
Study: 31175126

Group type: EXPERIMENTAL
Intervention: Research without prior consent (RWPC)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Consent discussions with the research team
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: RWPC approach
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Future diagnostic studies
Number of subjects: 20
Study: 31175167

Group type: EXPERIMENTAL
Intervention: Regorafenib 160 mg once daily for 3 weeks per 4-week cycle
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 59
Study: 31175375

Group type: EXPERIMENTAL
Intervention: Revive SE stent retriever
Number of subjects: 100
Study: 31175500

Group type: EXPERIMENTAL
Intervention: Capnography monitoring
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Capnography and Integrated Pulmonary Index™ algorithm (IPI)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Standard monitoring
Number of subjects: 250
Study: 31176355

Group type: EXPERIMENTAL
Intervention: Natalizumab treatment
Number of subjects: 222
Study: 31176752

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 85
Study: 31177537

Group type: EXPERIMENTAL
Intervention: Vorinostat (SAHA), cladribine 5 mg/m², and rituximab (SCR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31177556

Group type: EXPERIMENTAL
Intervention: C9orf72 hexanucleotide expansion carriers
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Cervical spinal cord imaging
Number of subjects: 72
Study: 31177821

Group type: EXPERIMENTAL
Intervention: Fantom sirolimus-eluting bioresorbable scaffold
Number of subjects: 240
Study: 31177991

Group type: EXPERIMENTAL
Intervention: Intratumoral injections of LTX-315 (oncolytic peptide)
Number of subjects: 1
Study: 31178096

Group type: EXPERIMENTAL
Intervention: L-DOPA Monotherapy
Number of subjects: 47

Group type: COMPARATOR
Intervention: Ineffective antidepressant medication taper
Number of subjects: 47

Group type: COMPARATOR
Intervention: Medication-free period
Number of subjects: 47

Group type: COMPARATOR
Intervention: Inclusion criteria adherence
Number of subjects: 47

Group type: COMPARATOR
Intervention: Follow-up adherence
Number of subjects: 47
Study: 31178349

Group type: EXPERIMENTAL
Intervention: DNA ligase activity in PBMCs of patients with stable angina (SA)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: DNA ligase activity in PBMCs of patients with non-ST elevation myocardial infarction (NSTEMI)
Number of subjects: 124

Group type: COMPARATOR
Intervention: DNA ligase activity in PBMCs of controls
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Expression of DDR genes in patients with stable angina (SA)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Expression of DDR genes in patients with non-ST elevation myocardial infarction (NSTEMI)
Number of subjects: 124
Study: 31178998

Group type: EXPERIMENTAL
Intervention: Interactive phone telesystem
Number of subjects: 256
Study: 31179027

Group type: EXPERIMENTAL
Intervention: Behavioural interventions
Number of subjects: 458

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 458
Study: 31179061

Group type: EXPERIMENTAL
Intervention: Preoperative acute lung injury (ALI)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Coagulation and fibrinolysis factors (PAI-1 in BALF and TF in serum and BALF)
Number of subjects: 53
Study: 31179079

Group type: EXPERIMENTAL
Intervention: Circulating free tumor-derived DNA (ctDNA) from plasma
Number of subjects: 1311
Study: 31179103

Group type: EXPERIMENTAL
Intervention: β-blockers (metoprolol tartrate/metoprolol succinate/Bisoprolol Fumarate) within 24 hours of perioperative period
Number of subjects: 1309

Group type: COMPARATOR
Intervention: Non-β-blockers
Number of subjects: 1309
Study: 31179244

Group type: EXPERIMENTAL
Intervention: Trientine plus Carboplatin and Pegylated Liposomal Doxorubicin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31179386

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT-AFL)
Number of subjects: 586

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT-AFL) with loading dose
Number of subjects: 586
Study: 31179499

Group type: EXPERIMENTAL
Intervention: Self-reported frequency and estimated amounts of sodium intake from salt added at the table (HP 2020 methodology)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Measured sodium intake from duplicate salt samples collected on recall days
Number of subjects: 450
Study: 31179503

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate/emtricitabine preexposure prophylaxis (PrEP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Post-PrEP discontinuation
Number of subjects: 0
Study: 31179781

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided percutaneous microwave ablation
Number of subjects: 0
Study: 31180977

Group type: EXPERIMENTAL
Intervention: Opioid use
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Opioid dosage
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Opioid use/dosage
Number of subjects: 193
Study: 31180994

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 31181137

Group type: EXPERIMENTAL
Intervention: CommunityRx e-prescribing system
Number of subjects: 41

Group type: COMPARATOR
Intervention: Usual recruitment practices
Number of subjects: 41
Study: 31182031

Group type: EXPERIMENTAL
Intervention: CTRP3 levels below the 25th percentile
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: CTRP9 levels below the 25th percentile
Number of subjects: 168

Group type: COMPARATOR
Intervention: CTRP3 and CTRP9 concentrations
Number of subjects: 168
Study: 31182122

Group type: EXPERIMENTAL
Intervention: Diesel exhaust (DE) exposure for 3 days (6 hours/day)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Electric trains (control)
Number of subjects: 29
Study: 31182337

Group type: EXPERIMENTAL
Intervention: Fear of Hypoglycemia (FOH) assessed using the HFS-II questionnaire
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Participants with severe hypoglycemia in the previous 6 months
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Participants with higher HFS scores
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: FOH as determined using the HFS-II questionnaire
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Higher FOH
Number of subjects: 298
Study: 31182367

Group type: EXPERIMENTAL
Intervention: Opioid users
Number of subjects: 386

Group type: COMPARATOR
Intervention: Non-users
Number of subjects: 386
Study: 31182436

Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitors (TKIs)
Number of subjects: 0
Study: 31182488

Group type: EXPERIMENTAL
Intervention: Linoleic acid intake (n-6 PUFAs)
Number of subjects: 214029

Group type: EXPERIMENTAL
Intervention: Replacing saturated fatty acids with linoleic acid
Number of subjects: 214029
Study: 31182525

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-Piperaquine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mefloquine
Number of subjects: 0